BioCryst Sues Hetero to Protect Drug Worth $386 Million (1)

BioCryst Pharmaceuticals Inc. said in a federal lawsuit that copies of Orladeyo proposed by Hetero Labs Ltd. infringe three patents for the life-saving rare-disease treatment, which accounted for most of BioCryst’s 2024 US sales.

Hetero’s generic version of Orladeyo infringes US Patent Nos. 10,662,160, 11,117,867, and 11,618,733, related to the drug’s crystal formulation, according to a complaint filed Monday in the US District Court for the District of Delaware. Orladeyo prevents potentially fatal attacks caused by the condition, hereditary angioedema.

• HAE attacks cause sudden, severe swelling in various body parts, including the throat, which can be life-threatening. ...